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Abstract
Background: The genomes of many epithelial tumors exhibit extensive chromosomal
rearrangements. All classes of genome rearrangements can be identified using End
Sequencing Profiling (ESP), which relies on paired-end sequencing of cloned tumor
genomes.
Results: In this study, brain, breast, ovary and prostate tumors along with three breast
cancer cell lines were surveyed with ESP yielding the largest available collection of
sequence-ready tumor genome breakpoints and providing evidence that some
rearrangements may be recurrent. Sequencing and fluorescence in situ hybridization
(FISH) confirmed translocations and complex tumor genome structures that include co-
amplification and packaging of disparate genomic loci with associated molecular
heterogeneity. Comparison of the tumor genomes suggests recurrent rearrangements.
Some are likely to be novel structural polymorphisms, whereas others may be bona fide
somatic rearrangements. A recurrent fusion transcript in breast tumors and a
constitutional fusion transcript resulting from a segmental duplication were identified.
Analysis of end sequences for single nucleotide polymorphisms (SNPs) revealed
candidate somatic mutations and an elevated rate of novel SNPs in an ovarian tumor.
Conclusion: These results suggest that the genomes of many epithelial tumors may be far
more dynamic and complex than previously appreciated and that genomic fusions
including fusion transcripts and proteins may be common, possibly yielding tumor-
specific biomarkers and therapeutic targets.
Background
Cancer is driven by selection for certain somatic mutations including both point
mutations and large-scale rearrangements of the genome; thus, the genomes of most
human solid tumors are substantially diverged from the host genome. Many copy number
aberrations have been shown to be recurrent across multiple cancer samples. These
recurrent copy number aberrations frequently contain oncogenes and tumor suppressor
genes and are associated with tumor progression, clinical course, or response to therapy
[1]. Moreover, it is now possible to alter the clinical course of breast cancer by the
therapeutic targeting of amplified ERBB2 oncoprotein [2].
Structural rearrangements, particularly translocations, are frequently observed in solid
and hematopoietic tumors. In hematopoietic malignancies the importance of
translocations is well established, but their biological and clinical significance in solid
tumors remains largely enigmatic due to technical difficulties and complex karyotypes
that defy interpretation. Recently, a bioinformatics approach identified recurrent
translocations in ~50% of prostate tumors [3]. This discovery of recurrent translocations
in prostate tumors is important because it demonstrates their presence in a common solid
tumor and may make possible development of tumor-specific biomarkers and drug
targets. Therapeutics such as Gleevec that are directed toward tumor-specific molecules
may be more efficacious with fewer off-target effects than therapies aimed at molecules
whose structures and/or expression are not tumor-specific.
End Sequencing Profiling (ESP) is a technique that maps and clones all types of
rearrangements while generating reagents for functional studies [4-7]. To perform ESP
using bacterial artificial chromosomes (BACs), a BAC library is constructed from tumor
DNA, BACs are end sequenced, and the end sequences aligned to the reference human
genome sequence (
Figure 1). Previous ESP analysis of the breast cancer cell line MCF7 revealed numerous
rearrangements and evidence of co-amplification and co-localization of multiple
noncontiguous loci [6, 7]. Similarly complex tumor genome structures were recently
identified in cell lines derived from breast, metastatic small cell lung, lung
neuroendocrine tumor using BAC end sequencing [8].
We performed ESP on: one sample each of primary tumors of the brain, breast, ovary;
one metastatic prostate tumor; and two breast cancer cell lines, BT474 and SKBR3.
Hundreds of rearrangements were identified in each sample, some of which may encode
fusion genes. Fluorescence in situ hybridization (FISH) confirmed the presence of
translocations predicted by ESP in BT474 and SKBR3. Sequencing of 41 BAC clones
from cell lines and primary tumors validated a total 90 rearrangement breakpoints.
Mapping these breakpoints in multiple breakpoint spanning clones provided evidence of
numerous genomic rearrangements that share similar but not identical breakpoints, a
phenomenon analogous to the inter-patient variability of breakpoint locations in many
fusion genes identified in haematopoietic cancers. Comparison of rearrangements shared
across multiple tumors and/or cell lines suggests recurrent rearrangements, some of
which confirm or suggest new germline structural variants, while others may be recurrent
somatic variants. Analysis of single nucleotide polymorphisms (SNPs) in BAC end
sequences revealed putative somatic mutations and suggests a higher mutation rate in the
ovarian tumor.
ESP complements other strategies for tumor genome analysis including array
comparative genomic hybridization (aCGH) and exon resequencing by providing
structural information that is otherwise not available. New sequencing technologies [9]
promise to radically decrease the cost of ESP and thus make it widely applicable for
analysis of hundreds to thousands of tumor specimens at unprecedented resolution. The
current study previews the discoveries of such future large-scale studies, examines some
of the challenges these studies will face, and provides reagents (genomic clones) for
further functional studies, particularly for cell lines which have proved useful as models
for cancer research [10, 11].
Results
Tumor BAC libraries
Bacterial artificial chromosome (BAC) libraries were constructed from frozen samples
from two breast tumors and single tumors from the brain, ovary and prostate,
demonstrating that there is no tumor-specific bias for BAC library construction.
Approximately 50 mg to 200 mg of fresh frozen tumor specimen was used in the
construction of each library. All tumors were dissected to minimize contamination with
normal tissue. BAC libraries from the breast cancer cell lines BT474 and SKBR3 were
also constructed. Breast cancer cell lines were included in this study because their
genomes and transcriptomes are similar to those identified in primary breast [10, 11] and
are invaluable for functional studies. BT474 and SKBR3 were chosen because their
aCGH profiles are similar to the profile of previously studied MCF7 cell line [6, 7]. All
three cell lines have very high amplifications at the ZNF217 locus on 20q13 and very
high amplifications at chromosome 17. Table 1 lists the clinical characteristics of the
tumors and properties of the BAC libraries.
BAC end sequencing and mapping
End sequences of 4,198 BAC clones from the brain tumor library, 5,013 clones from the
metastatic prostate library, 5,570 clones from ovary tumor library, 9,401 and 7,623 clones
each from primary breast libraries, 9,580 clones from the BT474 and 9,267 clones from
the SKBR3 breast cancer cell lines were generated. The end sequences (59.7Mb in total)
were mapped to the reference human genome sequence, and the results are summarized
in Table 2. We analyzed end sequences that mapped uniquely to the reference sequence,
excluding those in repetitive regions, segmental duplications, or duplication-rich
centromeric and subtelomeric regions. The density of mapped end sequences in ESP
closely matched copy number profiles generated using tiling path BAC arrays [6].
Outside these regions, the distribution of mapped end sequences along the genome did
not display other significant gaps or high density arguing against any unusual cloning
bias or mapping artifacts. For comparison and further analysis, we included 29.7Mb of
sequence from 19,831 end sequenced clones from MCF7 and 701 end sequenced clones
from a normal human library (K0241) previously reported [7].
Each clone with uniquely mapped ends gives a BAC end sequence pair (BES pair). A
BES pair is a valid pair if distance between ends mapped on the normal human genome
sequence and the orientation of these ends and are consistent with those for a BAC clone
insert; otherwise, the BES pair is invalid (Figure 1). An invalid pair indicates a BAC
clone that may span a genomic rearrangement. These are relatively rare, comprising 2.1-
4.3% of the mapped BES pairs (Table 2 and Table S1 in Additional data file 1). The
largest fractions of invalid pairs are observed in the three breast cancer cell lines, with the
greatest (4.3%) observed in MCF7. The majority of these invalid pairs map to amplicons
known to co-localize with other loci. DNA within these structures is highly rearranged
[4-7]. Among the primary tumors, the greatest fraction of invalid pairs is in the prostate
metastasis library (Table 1).
For each library, we formed BES clusters grouping invalid pairs with close locations and
identical orientations that are consistent with the same genome rearrangement [4]. Each
BES cluster provided evidence that the inferred rearrangements are not experimental
artifacts. We identified numerous BES clusters in each tumor (Table 2). The fraction of
end-sequenced clones that lie in clusters is much lower for clinical tumor samples than
cell lines, possibly due to the lower sequence coverage, normal tissue admixture, or
greater genomic heterogeneity in the primary tumors. Moreover, the coverage of the
genome by valid pairs was significantly lower than either predicted by Lander-Waterman
statistics or obtained by modeling using matched in silico BAC libraries [See Additional
data file 1 and Figures S1 and S2 in Additional data file 2]. This apparent reduction in
coverage is likely a result of differing amounts of aneuploidy and genomic heterogeneity
in the samples.
Sequencing rearrangement breakpoints
We performed low coverage sequencing of 37 BAC clones corresponding to invalid BES
pairs and combined this data with 10 previously sequenced MCF7 BACs [7]. For each
BAC, 96 3-kb subclones were end-sequenced, and subclones spanning the breakpoints
identified. These subclones were then sequenced to pinpoint the breakpoints more
precisely. This procedure identified 90 rearrangement breakpoints in 41 BACs with
some BACs containing multiple breakpoints (Table 3 and Table S2 in Additional data file
3). Breakpoints in six clones could not be identified due to repetitive elements and/or
genome assembly problems [See Additional data file 1]. The sequencing of these 41
clones confirmed the genomic locations of the BES determined by ESP and identified
translocation breakpoints in primary tumors of the breast, brain, ovary, and a metastatic
prostate tumor. In the breast cancer cell line MCF7, all clones with multiple breakpoints
mapped to a highly rearranged amplicon of colocalized DNA from chromosomes 1, 3, 17,
and 20, consistent with an earlier report [7] demonstrating that up to 11 breakpoints can
be present in a single 150-kb clone.
Of the 90 breakpoints identified in these 41 BACs, 63 were sequenced, and the remaining
27 were localized to 3-kb subclones. Since gross genomic rearrangements result from
aberrant double strand break (DSB) repair, we analyzed the rearrangement breakpoints
for signatures of the two major DBS repair mechanisms: non-allelic homologous
recombination and non-homologous end joining (NHEJ). We analyzed the repeat content
and structure of the 63 breakpoint junctions, 53 of which were non-redundant [See Table
S3 in Additional data file 3]. These 53 non-redundant junctions encompass 31
translocations, 12 deletions and 10 inversions. Two junctions (representing two
translocations) contain Alu elements spanning the breakpoints and are consistent with
DSB repair by Alu-mediated non-allelic homologous recombination. All of the remaining
junctions (51/53, 96%) are consistent with NHEJ repair and either span microhomology
regions ranging in size from 1 to 33 bp (45/51) or lack any homology (6/51) between the
two regions involved in a particular rearrangement. We find insertions at the junction site
ranging from 1 to 31 bp in 7/51 NHEJ events. Twenty of the 106 breakpoint sites deduced
from the non-redundant junction analyses are located within regions of known structural
variation.
Of the 90 breakpoints, 72 are predicted to alter gene structure resulting in either gene
fusions or fusions of gene fragments to intergenic regions. This high proportion reflects a
nonrandom selection of clones for sequencing, with priority given to clones likely to
encode fusion genes [12]. Of the remaining 18 breakpoints, 3 indicate deletions of
multiple genes. For example a breakpoint on chromosome 17 indicates a deletion of five
genes (EFCAB3, METTL2A, TLK2, MRC2, and RNF190). An additional 7 breakpoints
are located within genes and may result in intragenic rearrangements (e.g. the DEPDC6
gene on chromosome 8). The remaining 8 breakpoints are either rearrangements
involving intergenic regions or microrearrangements within introns.
Breakpoint Heterogeneity
BAC clones in amplicons such as those on chromosomes 1, 3, 17, and 20 in MCF7 are
highly over-represented and consequently form large BES clusters of invalid pairs.
Sequencing of a few of these clones [7] revealed that they often span multiple
breakpoints. We assessed whether all clones in a BES cluster share the same complex
internal organization by assaying the presence of sequenced breakpoints by PCR. In
total, we examined 23 breakpoints in 41 clones from seven BES clusters. The majority
(69/96) of the PCR assays indicated that breakpoints are shared between clones in the
same BES cluster. Surprisingly 5 of 7 BES clusters are heterogeneous in breakpoint
composition meaning that clones with nearby mapped ends do not necessarily span the
same breakpoints [See Table S4 in Additional data file 3]. For example, MCF7 clone
69F1 with one sequenced breakpoint is a member of a cluster with 11 clones, but only 8
of 11 clones contain the 69F1 breakpoint (Figure 2A, B). Another clone, 37E22, was
previously shown to contain four breakpoints [7]. Of the three clones in the BES cluster
with 37E22, two clones contain all four breakpoints, while one contained only one of the
breakpoints (Figure 2 C). In all cases, PCR validated the end locations of all negative
clones confirming the presence of alternative breakpoints in these clones. While the
mapped end sequences of the clones in these heterogeneous clusters confirmed that they
fuse similar genomic loci, we hypothesize that similar rearrangements occurred in
multiple copies of these loci, either due to earlier duplications in MCF7 or genomic
heterogeneity in different cells in the MCF7 population. While such variability in
breakpoint location, or breakpoint wandering, is observed in fusion genes shared across
multiple patients (e.g. the BCR-ABL gene in leukemia [13] and there are numerous
reports of genomic heterogeneity in cell lines [14, 15], this is the first time that it has
been observed on a microgenomic scale within a single sample.
Rearrangement validation
We validated a subset of breakpoints detected in the BT474 and SKBR3 breast cancer
cell lines using dual-color FISH. Normal BAC clones were selected that flank the
predicted breakpoints in the reference human genome, and FISH was performed to
metaphase spreads from the cell lines. Four BT474 and two SKBR3 breakpoints were
confirmed using dual color FISH (Figure 3). In addition DNA fingerprinting was
employed [16-20] on a subset of clones from the MCF7, brain and breast (B421) BAC
libraries. Excellent correlation between BES mapping and fingerprint mapping was
observed: fingerprint analysis confirmed the absence of the rearrangements in 250 of 261
(96%) BAC clones predicted not to span rearrangement breakpoints and confirmed the
presence of breakpoints in 154 of 226 (68%) clones predicted to span genomic
breakpoints by ESP [21].
Identification and analysis of recurrent breakpoints
We clustered BES pairs from all ESP datasets together and identified 62 recurrent
clusters that contain BES pairs from multiple samples whose mapped ends are close.
Recurrent clusters may be caused by recurrent somatic mutations, structural
polymorphisms [22], mapping problems or assembly errors in the reference genome.
Most recurrent clusters (60/62) fall into two classes: (i) mapping to
pericentromeric/subtelomeric regions (9) or (ii) micro-rearrangements (56), defined here
as rearrangements with breakpoints less than 2 Mb apart. Five clusters fall into both
classes. For the micro-rearrangements, 21/56 (38%) overlap known structural variants
[23] [See Table S5 in Additional data file 3], nearly a three-fold enrichment over the 15%
of non-recurrent clusters corresponding to known structural variants. The remaining 35
clusters may detect novel structural variants or cancer-specific rearrangements. For
example, a pericentric inversion on chromosome 11 was identified in two breast tumors
and all three breast cell lines [See Table S6 in Additional data file 1]. Other examples
include an 820-kb deletion in 17q23.3 in MCF7 and BT474 that contains the TRIM37,
GDPD1, YPEL2, DHX40, and CLTC genes and a 4 Mb deletion of gene-rich region in
10q11.22-10q11.23 in BT474 and a primary breast tumor (CHORI514) [See Table S6 in
Additional data file 1 and Figure S3 in Additional data file 2].
The largest number of BES clusters is found in the ESP datasets from the breast cancer
cell lines BT474, MCF7, and SKBR3. ESP identifies known amplicons, deletions, and
translocations present in these cell lines [24-26]. We searched for genomic loci that
contain a rearrangement breakpoint in at least two of these three cell lines. To minimize
the possibility of experimental errors, we first restricted consideration to rearrangement
breakpoints identified by a BES cluster in each cell line. We identified six examples of
such recurrent rearrangement loci. Four loci shared between MCF7 and BT474 map to
the 20q13.2-20q13.3 amplicon and have ends clustered within 2 Mb (Figure 4 A,B). It
might be significant that the breakpoints in MCF7 occur in and/or truncate BCAS1,
possibly explaining its total lack of expression in MCF7 despite being amplified [27]. In
contrast, BCAS1 is highly amplified and expressed in BT474 [27], and the breakpoints
map immediately distal to BCAS1 (Figure 4A). In addition, the regular spacing of
breakpoints in this locus is suggestive of breakage/fusion/bridge (B/F/B) cycles [7]. Two
additional loci are common to BT474 and SKBR3. One locus includes breakpoints that
cluster within ~ 500 kb of the ERBB2 gene that is amplified and over-expressed in these
cell lines [26]. In SKBR3, these breaks colocalize the ERRB2 locus with an amplified
region from chromosome 8 (Figure 4C). In the last example, breakpoints in BT474 and
SKBR3 are predicted to disrupt the ubiquitin protein ligase gene ITCH at 20q11.2. When
considering rearrangement breakpoints defined by all invalid pairs, rather than only BES
clusters, we identified 88 recurrent rearrangement loci across the three breast cancer cell
lines [See Table S7 in Additional data file 3].
Identification of fusion transcripts
Comparison of breakpoints revealed by ESP and putative fusion transcripts identified in
public EST databases provides evidence for expressed gene fusions. In one case, ESP
identified two BAC clones spanning an apparent 1q21.1;16q22.2 translocation in MCF7
and a primary breast tumor, (MCF7_1-30J11 and 2B421_023-O08, respectively). Both
clones were sequenced, and found to span identical breakpoints [See Table S8 in
Additional data file 3]. An EST clone DR000174 was identified in Genbank that co-
localizes with the sequenced breakpoint in BAC clones. This EST fuses a part of exon 6
with an adjoining intron of the HYDIN gene to an anonymous gene represented by a
cluster of spliced EST sequences. RT-PCR provided clear evidence that the fusion
transcript is expressed in 16 of 21 breast cancer cell lines (Figure 5A and Additional data
file 1), normal cultured human breast epithelial cells, and a wide range of normal human
tissues. Recently, a 360-kb segmental duplication containing the HYDIN locus was
identified on chromosome 1q21.1 [28]. This duplication event created the HYDIN fusion
gene and explains the observed apparent 1q21.1;16q22.2 translocation. To our knowledge
this is the first example of a segmental duplication resulting in an expressed fusion gene.
In a second example, a putative fusion transcript (GenBank accession CN272097) and the
breakpoint in MCF7 clone 1-97B19 identify a complex rearrangement fusing the
SLC12A2 gene and EST AK090949 on chromosome 5. RT-PCR provided evidence for
expression of the fused transcript in 5 of 21 breast cancer cell lines and in higher passage,
but not lower passage, human mammary epithelial cells (Figure 5B). In addition, RT-
PCR provided clear evidence of alternative splicing of this transcript. Interestingly, we do
not detect expression of this fusion transcript in MCF7 possibly due to differences
between the location of this breakpoint in MCF7 and the EST. If this fusion is the result
of a somatic mutation in breast tumors and not a structural polymorphism, it will
represent the first recurrent fusion transcript reported in breast cancer. Additional studies
aimed at analysis of the presence of this transcript in clinical specimens are underway.
Thus, paired-end sequencing approaches are useful for the elucidation of genome and
transcriptome remodeling in phylogenetics and cancer.
SNP Analysis
The availability of ~89 Mb of sequence from 97,680 mapped BES made it possible to
identify single nucleotide polymorphisms and candidate somatic mutations.
Approximately 62.5% (61,013) of the mapped BES contained at least one mismatch in
the alignment between the BES and the reference genome. From these mismatches, we
identified 115,444 candidate SNPs defined as a single base mismatch flanked on both
sides by at least one matched base. Many of these mismatches are likely sequencing
errors to be expected when examining raw end sequences. Thus, we applied the
following filtering criteria to discard low confidence SNPs: the PHRED score [29] of the
SNP, the mean PHRED score of the five bases centered on the SNP, and the mean
PHRED score of the entire BES containing the SNP all must exceed 30. Approximately
58% of the candidates SNPs were removed by this filtering step, leaving 48,243 SNPs.
Of these, 40,659 (84%) are known variants recorded in dbSNP: the probability of this
event if our SNP candidates were randomly distributed on the genome, as would be the
case if they were largely caused by sequencing errors, is vanishingly small. Thus, our
stringent filtering criteria enriched for true SNPs instead of sequencing errors. 7,584
(~16%) of the valid SNPs are novel [See Table S9 in Additional data file 1], and 77 of
them are recorded in more than one BES [See Table S10 in Additional data file 3]. All of
the cancer samples show significantly (P < 10-23) higher rates of novel SNPs than the
normal sample; moreover, the ovarian tumor has a significantly (P < 10-39) higher rate of
SNPs than the other cancer samples (Figure 6). While some of these novels SNPs are
likely to be sequencing errors or rare genetic variants, these cases do not explain the
observed biases across samples.
The transition:transversion ratio of these novel candidate SNPs is 1.8, which is lower
than the value 1.95 reported for BAC end sequencing of mouse strains [30], comparable
to the value 1.85 in coding exons of breast tumors [31], but significantly lower than the
value 7.4 in coding exons of colorectal tumors [31]. Moreover, the mutational spectrum
of these novel SNPs [See Table S11 in Additional data file 1] varies across the tumor
types, and many of these variations are significant (P < 0.00001 by 2 test). An excess of
C:G! T:A transitions over T:A! C:G transitions is observed in all samples except one
of the breast tumors, similar to recent reports from exon resequencing studies in tumors
[31, 32]. However, the asymmetry in the frequency of these two types of transitions is
generally less than reported in these studies. Interestingly, the strongest asymmetry is
found in our brain sample, in agreement with [32] who find the greatest asymmetry in
gliomas. Examination of the frequency of variation at dinucleotides [See Table S12 in
Additional data file 3] reveals an excess of C:G! G:C transversions occurring at
TpC/GpA dinucleotides consistent with the report of [32]. The explanation for this bias
is not known, but is hypothesized to represent a cancer-specific mutational mechanism or
environmental exposure.
Thirty-five of the 7,584 novel SNPs were identified in coding regions [See Table S13 in
Additional data file 3]. Of these, 24 are non-synonymous changes that occur in a diverse
group of genes including the genes IRAK1 (possibly mutated in breast tumor B421) and
RPS6KB1 (possibly mutated in BT474), which were previously identified as somatic
mutations in breast cancer [33]. Analysis of gene annotations recorded in GO with the
DAVID tool [34] that corrects for differences in the sizes of annotated gene families,
identified six genes classified as “transition metal ion binding” (P = 0.07) including the
zinc binding proteins ZNF217, ZNF160, ZNF354C, ZDHHC4, and ANKMY1.
Interestingly, the SNP in ZDHHC4 occurs in the zinc finger domain as defined in
UniProt. Examination of SNPs in amplified regions in MCF7, BT474, and SKBR3 did
not suggest any correlation between SNP rate and amplification: some amplicons harbor
a high number of sequence variants, while others have relatively few [See Table S14 in
Additional data file 3].
We resequenced 17 candidate SNPs found in the breast cancer cell lines [See Table S15
in Additional data file 3] and confirmed 11/17 (64.7%), a success rate is very similar to
the 68% reported in large-scale resequencing of exons [31]. Of the six remaining cases,
four were sequencing failures, while two contained double signals in the ABI
electrophoregrams at the SNP site, with the reference peak being the dominant one.
Thus, it is possible that these SNPs are heterogeneous in the cell lines. Therefore, only
2/17 candidate SNPs (11.8%) were contradicted by resequencing. Since 2 of the 11
validated SNPs, plus two that were not validated were also found in a more recent update
of dbSNP (128), we checked all 7584 novel SNPs against dbSNP Build 128 and found
that 1698 (22%) were present, providing further evidence that our SNP filtering criteria
are enriching for true sequence variants rather than sequencing artifacts.
Discussion
The importance ascribed to different types of genome aberrations in cancer is frequently
directly coupled to the technology available to measure them: classic cytogenetics
demonstrated the functional significance of translocations in tumors with simple
karyotypes, while LOH, CGH and array-CGH studies have led to an explosion of interest
in recurrent copy-number aberrations. More recently, targeted [32, 35] and whole
genome exon re-sequencing [31] has shown the importance of coding mutations. The
Cancer Genome Atlas project [36] promises to drastically increase the number of known
coding somatic mutations. However, it is likely that structural rearrangements in tumor
genomes are as important to tumor biology and the development of biomarkers and
therapeutics as are coding point mutations [37, 38]. We have demonstrated that ESP
provides direct access to the structural complexity of tumor genomes by identifying and
cloning all classes of structural rearrangements including fusion genes and their
transcripts. ESP also proved to be a powerful tool for analysis of structural polymorphism
present in the normal human genome [39, 40]. Moreover, identification of the HYDIN
gene fusion by ESP reveals that duplicon-mediated genome rearrangements can result in
expression of structurally novel genes. Using this approach it is also possible to survey
the spectrum of mutations and/or SNPs present in a tumor genome in an unbiased
fashion.
Many of the recurrent breakpoints that we identified arise from micro-rearrangements of
less than 2 Mb (Figure 4). Although some of these rearrangements are likely to be novel
structural polymorphisms, micro-rearrangements have also been observed in evolution
[41, 42] and in some tumors [43]. Since micro-rearrangements are largely invisible to
cytogenetic techniques, the collection of the breakpoints reported in this paper provides
an excellent resource for future studies of the mechanisms, prevalence, and consequences
of these micro-rearrangements in tumorigenesis.
Sequencing BAC clones identified by ESP was performed to localize and validate ~90
breakpoints in this and a previous study [7]. To our knowledge, this is currently the
largest collection of sequenced rearrangement breakpoints in cancer. Importantly, this
collection can be easily extended as needed, since ESP created also the largest collection
to date of hundreds of sequence-ready breakpoint-spanning BAC clones. Most
breakpoint- spanning BAC clones, including all BAC clones sequenced from primary
tumors, contain single breakpoints. However, in the three cell lines, 17 clones containing
multiple breakpoints were identified and confirmed by PCR. These observations were
supported by DNA fingerprinting (Dr. Marco Marra; personal communication and [21]).
The observed differences between the primary tumors and cell lines may be due to
genomic heterogeneity (and consequently lower sequence coverage) of tumor samples,
differences in tumor type and/or stage, or intrinsic differences in genomic organization
between cell lines and primary tumors. It will be informative to perform ESP on primary
breast tumors with copy-number profiles very similar to those of the cell lines studied
here [10, 11] and to establish the degree of the structural similarity of the samples with
similar copy-number and expression profiles.
Our analyses of breakpoint junction sequences revealed that the overwhelming majority
of identified rearrangements (96%) are consistent with aberrant NHEJ repair. This
observation is consistent with the previously reported predominant role of non-
homologous recombination in generation of pathologic translocations [44] and in
frequent rearrangements at chromosomal ends [45]. While there are reports of
associations between locations of cancer breakpoints and evolutionary breakpoints [46],
ESP data did not reveal a significant association in our samples (data not shown).
We used sequenced breakpoints to refine the mapping of amplicon structures in MCF7
using PCR in seven independent BES clusters. This process identified breakpoint
heterogeneity in five clusters (Figure 2 and Figure S3 in Additional data file 2). One
explanation for this phenomenon is variability in the location of breakpoints in multiple
fusions of the same loci, analogous to the variability of breakpoints in fusion genes in
hematopoietic malignancies. Alternatively, the heterogeneity might reflect early events
present in a minority of cells in the population. To our knowledge, this is the first
example of structural heterogeneity observed on a molecular level in tumor genomes.
Analysis of SNPs in BAC end sequences identified elevated rates of SNPs in each tumor
sample compared to the normal sample, with the ovarian tumor exhibiting a rate
significantly above the other samples. Although the ability to distinguish somatic
mutations from sequencing errors or germline mutations is limited in the present study,
there is no reason to suspect that these confounding factors vary enough between samples
to explain the observed differences. The mutational spectra of SNPs in these samples
share some features with those from exon resequencing studies [31, 32], but there are also
many differences. These differences might be due to different mutational biases in
coding regions, but further study is needed to support this hypothesis. Given that the
BES arise from a genome-wide survey, it is not surprising that we identify few candidate
mutations in coding regions. However, it is intriguing that even the relatively small
numbers of putative mutations are enriched for zinc finger genes, including the known
breast cancer oncogene ZNF217 [27, 47, 48].
Using ESP it is possible to reconstruct tumor genome structure and evolution [4-7]. ESP
data from the three breast cancer cell lines identify clones that fuse noncontiguous
amplified loci, possibly suggesting functional coupling of co-amplified genes. The
discovery of recurrent breakpoints and regularly spaced breakpoints in the cell-line data
could be a molecular signature of breakage/fusion/bridge (B/F/B) cycles [7]. In some
cases, ESP data suggest a specific temporal progression where amplification follows
translocations or deletions. For example, a cluster of 19 clones span a 17;20 translocation
in MCF7. This coverage is highly unlikely (P < 10-20) for a non-amplified locus and PCR
mapping confirmed identical breakpoints in these clones. The most parsimonious
explanation is that the translocation preceded the amplification. In a second example, a
cluster of six BT474 clones spans a deletion. Once again the simplest explanation is that
the deletion preceded amplification of the surrounding locus, since a cluster of size six
clones is highly unlikely (P ≈ 10-5) in a non-amplified locus. Interestingly, this deletion
may truncate the THRA1 gene as reported in [25] and fuse it to the SCAP1 gene.
Amplification of a breakpoint might occur because the fused genomic region encodes a
fusion gene that confers a selective growth advantage. Alternatively, amplification might
be a random byproduct of genomic instability near the rearrangement breakpoint.
Regardless, the breakpoint information is valuable for determining the temporal evolution
of tumor genome organization.
The identification of TMPRSS2 translocations in ~ 50% of prostate tumors [3]
underscores the significance of structural rearrangements in solid tumors. While our
prostate sample does not contain the TMPRSS2 translocation (Mark Rubin, personal
communication), ESP mapping and breakpoint sequencing provide numerous examples
of possible gene fusions, including the previously published BCAS4/3 fusion in MCF7.
Moreover, integration of public EST data with ESP data demonstrates that this approach
can identify fusion transcripts en masse. We identified a fusion transcript that results
from an evolutionarily recent rearrangement of the normal genome and obtained evidence
for the first recurrent fusion transcript in breast cancer. In this study the clonal coverage
of tumor genomes ranged from only .15 to .7-fold redundancy. It is probable that many
additional gene fusions will be identified upon deeper paired end analysis of both normal
and tumor genomes and transcriptomes.
The extension of ESP to multiple tumor types demonstrates that its application is not
restricted to specific tumor types and that ESP functions well even with small tumor
specimens. This is important because advances in diagnostics have resulted in a reduction
in the average volume of many surgically excised tumors. For example, the average size
of breast tumors excised before 1985 was 25 mm, while after 1985 it decreased to 21 mm
[49], a 1.6 fold decrease in the volume of excised breast tumors. Moreover, tumor
heterogeneity and normal cell admixture necessitates dissection further reducing
subsequent yields of tumor cell DNA. Finally, clinically annotated tumor specimens are
an extremely valuable resource and should be used as sparingly as possible. Therefore, it
is significant that we were able to construct a tumor BAC library from less than 20 mg of
a frozen and partially necrotic tumor (B421). DNA yields from the tumors suggest that
libraries comprised of 200,000-400,000 clones are possible, meaning that the genomes of
these tumors can be immortalized and made widely available. This study demonstrates
the utility of ESP for whole genome screening of SNPs/mutations. The immortalization
of the tumor genome in a clone library is important, since some studies report
underestimation of the mutation load because of heterogeneity in tumors [50], and
overcoming this problem will require either development of the novel software, or
implementation of the novel sequencing technologies allowing analysis of single DNA
molecules [51]. Since clone libraries can be duplicated and their DNA pooled, it becomes
feasible to perform large exon resequencing projects on small tumors such as those of the
breast and prostate. In addition, since BAC clones contain DNA from a single tumor cell,
identification of rare SNPs/mutations in heterogeneous tumors is theoretically possible in
a manner analogous to the identification of breakpoint heterogeneity in tumor amplicons
reported here. Finally, the ability to rapidly identify sequence variants in DNA pools and
to then recover the physical clone means that studies aimed at determining the biological
relevance of the variants are possible using established in vivo and in vitro systems.
ESP is less impeded by tumor heterogeneity or contamination by normal cells than is
aCGH, because each end-sequenced clone originates from a single DNA molecule from a
single cell. Deep sequencing of many clones allows one to overcome normal tissue
admixture and enables direct measurements of heterogeneity and detection of rare events.
Eventually it will be possible to apply techniques from metagenomics [52] to study the
heterogeneous pool of cells present in early stage tumors with the goal of identifying the
earliest informative biomarkers and therapeutic targets. At present, the relatively high
cost of ESP limits its application to a small number of tumors, but advances in massively
parallel sequencing technologies capable of paired-end sequencing (reviewed in [9]) will
permit large-scale ESP studies at a fraction of the current cost. However, much of the
cost savings realized by the current crop of next-generation sequencing technologies
result from skipping the immortalization of the tumor genome as a clone library. Such
cloning enables further sequencing of breakpoints and evaluation of their functional
significance via in vitro and in vivo assays [7]. Combining ESP with such assays will
enable tumor progression studies aimed at identification of events linked to initiation,
progression, and metastasis. Thus, while the selection of a particular implementation of
ESP will be driven by the cost/benefit analysis for the specific goals of the project, paired
end sequencing approaches promise to revolutionize our understanding of the complex
organization of the genomes of solid tumors.
Materials and methods
BAC Library Construction
Breast cancer cell lines were obtained from UCSF cell culture facility. Clinical tumor
specimens were obtained from Bay Area Breast Oncology Program (breast tumors), rapid
autopsy program at University of Michigan [53], and the University of Texas M.D.
Anderson Cancer Center SPORE in ovarian cancer (ovarian).
Library preparation was carried out as described previously [7] (see detailed protocol at
[54]). Briefly, fresh frozen tissue (0.1 to 0.15 g) was slowly thawed on ice, ground and
resuspended in 0.6 mL of 1X PBS (pH 7.0). The suspension was pre-warmed to 42°C in
water bath and mixed with an equal amount of a warm 1.5% solution of low melting-
point agarose. The partial restriction was carried out for 1 hour on ice, followed with
incubation for 10 min at 37°C and stopped by addition of 0.1 volume of 0.5 M EDTA.
Additional processing associated with isolation of high molecular weight DNA,
construction of BAC libraries and end-sequencing of BAC clones was carried out as
previously reported [7].
ESP Data Analysis
We employed a two-step procedure that involved first mapping the BAC end sequence
(BES) data onto the human genome sequence (NCBI Build 35, May 2004), and then
filtering the mapping results. The mapping step is accomplished using BLAT [55]. A
location is assigned if at least 50 bp of a BES aligned to the reference genome sequence
with at least 97% identity. If the BES hit multiple locations in the genome, the position
of the longest hit with highest identity was chosen and the BES was designated as being
“ambiguously mapped” and excluded from further analysis. Finally, BES mapping to
known segmental duplications, as defined by the SegmentalDups track of the UCSC
Genome Browser were removed. Only clones corresponding to unique BES pairs were
retained. BES mappings are available as a custom track for the UCSC Genome Browser
at [56].
BES pairs with BES mapping to the same chromosome and having opposite convergent
orientations (i.e., a pair of the form ([chrom1, loc1, strand1], [chrom2, loc2, strand2])
with chrom1 = chrom2, loc1 < loc2, strand1 = “+”, and strand2 = “-“) were identified.
The distribution of distances between mapped ends (loc2 – loc1) was used to define the
length distribution of the BAC libraries. BES pairs with ends on the same chromosome
and having convergent orientations on opposite strands and distances in the 99.5%
quantile of this distribution were classified as valid. Other BES pairs were classified as
invalid and thus candidate rearrangements in the tumor. Note that the distance criterion
was very permissive and might misclassify clones harboring small indels as valid.
Overlapping valid pairs were combined into “contigs”, while invalid pairs were clustered
into sets according to whether their locations were close enough to be explained by a
single rearrangement event [4-7]. Invalid pairs (or clusters) were classified as potential
indels, inversions, or translocations according to the location and orientation of their ends
[See Table S1 in Additional data file 1].
Custom software was used to visualize the mapping results as described in [6]. A plot of
BES density generated a copy-number profile for the entire tumor genome, as the overall
number of BES per given genomic interval is roughly proportional to copy number.
Known Structural Variants
Locations of previously reported structural variants were downloaded from the Database
of Genomic Variants [23, 57]. Clusters of invalid BES pairs were labeled as “explained”
by the known structural variant if the locations of the variant overlapped the locations of
an end sequence pair in the cluster, and the type of variant was consistent with the
orientations of the mapped end sequences in the clusters. That is, pairs with convergent
orientation are consistent with insertions and deletions (i.e. copy number variants), while
pairs with the same orientation are consistent with inversions. We did not require precise
overlap between the breakpoints of the invalid BES pairs and the breakpoints of the
structural variants because both types of breakpoints were only approximately known.
Note that multiple structural variants might “explain” a cluster because the structural
variants in the database were merged from different experimental sources and have some
redundancy [58].
BAC Sequencing
BAC DNA was purified from 250 ml overnight culture using the Qiagen columns
(Qiagen). Approximately 2 µg of BAC DNA was mechanically sheared using the
HydroShear (GeneMachine Inc.), end-repaired with the Klenow enzyme and T4 DNA
polymerase, size-selected for 3±0.5 kb fragments on agarose gels, and cloned into a
pUC19 vector. Individually picked subclones were grown on 96-well plates overnight in
LB plus 200 µg/ml ampicilin and 10% glycerol. Plasmid DNA was prepared from the
arrayed cells using the TempliPhi kit (GE/Amersham) according to the manufacturer’s
protocol. 3 kb subclones were end-sequenced using BigDye terminators (Applied
Biosystems) and capillary sequencers. Quality of the sequence reads were determined by
Phred score [29], and only sequences greater than Q20 were included in the analysis.
Analysis of rearrangements breakpoint junctions
Breakpoint junction sequences were aligned to the Human Genome Assembly (NCBI
Build 35, May 2004) using BLAT [55], and the alignments were analyzed for the precise
position of the breakpoint and presence of microhomologies. Breakpoint sequences were
also analyzed for their repeat content using the RepeatMasker program and for their
overlap with known copy number polymorphic regions using the Structural Variation
track of the Genome Browser. The mechanism of each rearrangement was deduced from
the alignment of the breakpoint junction sequence to the native sequences of the two
regions participating in the rearrangement, and the number of total DSBs calculated as
previously described [45].
SNP Analysis
Out of the ~70,000 clones sequenced for this and previous studies, we selected the 97,860
BES that mapped to unique loci on the hg17 reference genome with a minimum BLAT
identity score of 97%. The mean PHRED score [29] of these BES is 51. 61,013 of the
selected BES contained at least one mismatch. Runs of multiple contiguous mismatches
and indels were not considered when defining a SNP. We identified 115,444 candidate
SNPs, which we defined as a single base mismatch flanked on both sides by at least one
matched base. 67,201 (58.21%) of these candidate SNPs were attributed to possible
sequencing errors, because the PHRED score of the SNP, or the mean PHRED score of
the five bases centered on the SNP, or the mean PHRED score of the entire BES was
below 30. Candidate SNPs were not considered tumor-specific if their location and
nucleotide change matched a known SNP in dbSNP Build 124. Coding SNPs were
identified as those than lie in exons annotated from the “Known Genes” track of the
UCSC Genome Browser. The observed rates of SNPs of each type of nucleotide
substitution were compared across different samples using the chi-square test.
Enrichment of GO terms for the genes containing candidate SNPs was computed with the
DAVID tool [34], which computes P-values for enrichment correcting for the size of the
gene sets in each term. We used the LiftOver tool from the UCSC Genome Browser [59]
to identify the locations of each novel SNP in the latest build (Build36) of the human
reference genome and examined whether these SNPs were present in dbSNP Build 128
using the snp128 table. The validation of candidate SNPs/mutations was performed by
direct genomic sequencing of the DNA amplified from the cell line used for ESP.
Reverse-Transcript PCR
RT-PCR experiments were carried out as described in [60]. Primer sequences and
conditions are presented in table below. We employed a nested PCR strategy to increase
specificity and sensitivity of our assay. All PCR reactions were carried out in 25 µl
reaction volumes using following program: initial denaturation of DNA – 4 min at 94°C,
30 to 35 cycles of 15 sec at 94°C, 30 sec at 60°C, 45 sec at 72°C. We have used ~100 ng
of cDNA for the first reaction with outer primers, and 1 µl of the resulting PCR reaction
for the second round using inner primers. Following primers were used: DR00074:
AGGAAAAGGCCTTGAAGCTC and TGCTGTATTTGACAGGACAAGTG (outer
primers); GAGGACATGCTCCTACCTGTG and TGCTGTATTTGACAGGACAAGTG
(inner). For CN272097 we used CCAACGTGAGCTTCCAGAAC and
ACAGAAACGCCTCTTCTCATTTAG (outer); TATTATGATACCCACACCAACACC
and CTCCTGTTCGTGTCAGCAATAC (inner). The specificity of PCR reactions were
validated by sequencing at UCSF Genome Analysis Core.
Spectral karyotyping (SKY) and FISH analysis:
Cells lines were shipped to HPN. When cell lines reached 70% confluence, cells were
treated with colcemid (Roche, Indianapolis, IN) for 1 hour to arrest the cells in mitosis.
Metaphase chromosome suspensions were prepared first by treating cells with a
hypotonic solution (0.075M KCl), next, the cells were fixed using methanol: acetic acid
(3:1, vol/vol) and dropped onto slides in a humidity controlled chamber. The slides were
aged at 37°C for approximately one week. Chromosome preparations were hybridized
with either FISH probes or SKY probes for 72 hours. The protocols for preparation of
FISH/SKY probes, slide pre-treatment, slide denaturation, detection, and imaging have
been described previously and are available at [61]. Ten to 15 metaphase spreads were
analyzed per sample and scored for the following: chromosome number (ploidy),
numerical aberrations, and structural aberrations. Spectrum-based classification and
analysis of the fluorescent images (SKY) was achieved using SkyViewTM software
(Applied Spectral Imaging, Carlsbad, CA). The karyotypes of every metaphase spread
from all groups were characterized using the human chromosome nomenclature rules
described in ISCN, 2005.
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Figure Legends
Figure 1: Schematic of ESP. End sequencing and mapping of tumor genome fragments to the human
genome provides information about structural rearrangements in tumors. A BES pair is a valid pair
if distance between ends mapped on the normal human genome sequence and the orientation of these
ends and are consistent with those for a BAC clone insert; otherwise, the BES pair is invalid.
Figure 2: PCR validation of breakpoints in MCF7. (A) MCF7 clone 69F1 was sequenced and
contained a small piece of chromosome 1 (purple rectangle) to chromosome 17 (yellow rectangle).
Arrows on each rectangle indicate whether the fragment is oriented as in the reference genome
(pointing to right) or inverted (pointing to left). PCR primers were designed to amplify the
breakpoint and these primers were used to assay the other clones in the BES cluster with 69F1. Each
of the other clones in the cluster are indicated as lines below 69F1 with the endpoints of the lines
indicating the locations of the mapped ends relative to the ends of 69F1. The heterogeneous PCR
results might result from heterogeneity of the MCF7 cells, or the existence of multiple versions of this
breakpoint in MCF7 genome. (B) PCR results for the clones in (A). The expected size of the PCR
fragment is 600 bp. (C) PCR validation of breakpoints in sequenced clone 37E22 from MCF7 and
three additional clones in BES cluster all fusing nearby locations from chromosomes 1, 3, and 20.
Two other clones have the same complex internal organization as 37E22 with four rearrangement
breakpoints. However, clone 34J23 contains only one of these breakpoints suggesting that the
rearrangement history of this clone is different from that of the others in the cluster.
Figure 3: Use of dual-color FISH for to validate a BT474 genomic breakpoint. End sequences from
clone CHORI518_014-E04 clone were mapped to chromosomes 1 and 4. Clones RP11-692N22 and
RP11- 1095F2 were selected from the human RPCI11 library because their sequences map just
outside of tumor BES locations. These BACs were labeled with fluorescein and Texas Red,
respectively. (Top) Two chromosomes containing a merged yellow signal indicating juxtaposition of
both probes are indicated with white arrows (and labeled “a” and “b”). (Bottom) Each labeled
chromosome is shown with corresponding inverted-DAPI banded chromosome, and red and green
image layers. Black arrows identify the region where the red and green probes are juxtaposed to one
another.
Figure 4: Recurrent rearrangement loci in the three breast cancer cell lines. (A and B) Four loci on
20q13.2-13.3 shared by MCF7 and BT474 and (C) a locus near the ERBB2 amplicon shared by
BT474 and SKBR3. Colored boxes indicate the breakpoint regions for different BAC clones from
MCF7 (blue), BT474 (red) and SKBR3 (green) as a custom track on the UCSC genome browser. A
breakpoint region is defined as the possible locations of a breakpoint that are consistent with all the
BES in the cluster; thus, shorter boxes indicate more precise breakpoint localization. Arrows give
the strand of the mapped BES and thus point away from the fused region.
Figure 5: RT-PCR assays of fusion transcripts on a panel of breast cancer cell lines and normal
tissues. HMEC-P1 stands for normal human mammary epithelial cells (passage 1), HMEC-P4 stands
for HMEC passage 4 (higher passage). (A) RT-PCR reveals expression of DR00074 (HYDIN gene
fusion) in 16 of 21 tested breast cancer cell lines, normal cultured human breast epithelial cells, and a
wide range of normal human tissues. (B) RT-PCR validation of CN272097 a cDNA produced by a
complex rearrangement on chromosome 5 fusing the SLC12A2 gene and EST AK090949. The
results provide evidence for expression of the fused transcript in 5 of 21 breast cancer cell lines and
in higher passage but not lower passage human mammary epithelial cells (HMEC). Note that
MDAMB435 was recently demonstrated to be derivative of the M14 melanoma cell line and not from
breast [62], and the absence of the SLC12A2 fusion is this cell line is consistent with its absence is
other non-breast tissues.
Figure 6: Results of SNP identification in BAC end sequences. (A) The number of high quality
isolated SNPs in uniquely mapped BAC end sequences expressed per kilobase (Blue). Each tumor
sample has a significantly higher rate of SNPs compared to the normal library, while the ovarian
library shows a rate significantly higher than the other tumor samples. (Red) Fraction of SNPs not
found in dbSNP124. The ovarian library shows significantly higher rate of these novel SNPs. (B)
Mutational spectrum of SNPs for each of the samples. For C:G! T:A transitions and C:G! G:C
transversions, the fraction at CpG dinucleotides is indicated in red and yellow, respectively.
Tables
Library
Name
AA9 B421
CHORI-
514
MCF7 PM-1
CHORI-
510
CHORI-
518
CHORI-520
Clinical
sample
designation
AA9 B421 S104 MCF-7 25-48 860-7 BT-474 SK-BR-3
Organ site Brain Breast Breast
breast cancer
adenocarcinoma
(metastasis -
pleural
effusion)
Prostate
metastasis
Ovarian
carcinoma
ductal
carcinoma
breast cancer
adenocarcinoma
(metastasis -
pleural
effusion)
Therapies
applied
Radiotherapy
Chemotherapy
4 months
prior to
surgery
(CMF)
No
radiation
or chemo
prior to
surgery
N/A
Hormone
ablation,
palliative
radiotherapy
No therapy
prior to
surgery.
N/A N/A
Patient
status
Deceased
Deceased, no
recurrence
No
recurrence
for 10
years
N/A Deceased
Tumor
recurred
within 13
months
N/A N/A
Total
amount of
tumor
material
used for
library
construction
(mg)
100
150 (20mg
effective)
100 N/A 50 200 N/A N/A
Average
clone size (±
standard
deviation),
kb
129.1±38.3 136.4±29.2 166.1±53.2 148.0±30 N/D 149.3±28.8 179±23 154±25
Table 1: Clinical characteristics of the recurrent glioblastoma AA9, primary breast tumors B421 and
S104, ovarian tumor 860, prostate metastasis 25-48 and the breast cancer cell lines MCF7, BT474,
and SKBR3 used for BAC library construction. Average clone size was determined by PFGE analysis
of Not1-digested DNA from 30-100 clones. (N/D means that the number was not determined, while
N/A means that the number is not applicable for cell lines which can be grown in any amount and
whose clinical history is not available). The presence of a large blood clot in B421 sample reduced an
effective amount of tumor tissue to estimated 20 mg (out of ~150mg received from tumor bank).
MCF7 BT474 SKBR3 Breast Breast.2 Ovary Prostate Brain Normal
Library Name MCF7_1
CHORI-
518
CHORI-
520 B421 CHORI514 CHORI510 PM1 IGBR K0241
Num mapped
clones 12143 8044 7363 6972 5678 3946 3499 3238 609
Unique mapped
clones 11492 7547 6950 6540 5381 3714 3296 3051 568
Valid pairs 11001 7361 6763 6376 5268 3627 3200 2984 560
Number Contigs 6323 4135 4171 4365 3450 2877 2747 2573 548
Contig coverage 0.324 0.327 0.274 0.233 0.243 0.155 0.104 0.103 0.019
Invalid pairs 491 186 187 164 113 87 96 67 8
Fraction invalid 0.043 0.025 0.027 0.025 0.021 0.023 0.029 0.022 0.014
p-value 4.10E-04 0.056 0.032 0.051 0.133 0.080 0.020 0.113 NA
Number clusters 36 26 24 2 7 2 2 0 0
Invalid pairs
in clusters 164 61 64 4 24 4 4 0 0
Table 2: Results of end sequencing and mapping of each library. The fraction of invalid pairs is
calculated relative to the number of uniquely mapped pairs. The p-value is the probability that the
fraction of invalid pairs is the same as observed in the normal library, using a sample proportion test
with pooled variance.
Table 3: Summary of BAC sequencing. Breakpoints are indicated as sequenced if the nucleotide
sequence was obtained, or identified if the breakpoint was localized to 3 kb subclones.
Sample Clones with
identified or
sequenced
breakpoints
Total Number of
identified/sequenced
breakpoints
Intragenic
rearrangements
Gene:intergenic
fusions
Gene:gene
fusions
Intergenic:intergenic
fusions
MCF7 12 36/35 3 10 19 4
BT474 6 15/6 3 2 10 0
SKBR3 8 24/8 7 4 12 1
Breast
(2B421)
3 3/3 0 0 3 0
Breast
(CH514)
0 - - - - -
Ovary 4 4/4 0 0 4 0
Prostate 5 5/5 0 4 1 0
Brain 3 3/3 0 3 0 0
1) Clone 100-250 kb 
pieces of tumor
genome.
Human DNA
2) Sequence ends of 
clones (500 bp).
3) Map end sequences to 
human genome. 
Tumor DNA
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